Company profile: Oxford Biomedica
1.1 - Company Overview
Company description
- Provider of gene and cell therapy solutions, offering lentiviral LentiVector and AAV platforms for development and manufacturing of gene therapies, plus CDMO services for viral vectors including tech transferred-in execution of client-defined methods, process development, GMP manufacturing, and regulatory support.
Products and services
- CDMO services: GMP-compliant contract services that deliver viral vector process development, GMP manufacturing, and regulatory support for gene and cell therapy development and manufacture
- LentiVector® platform: Lentiviral-based gene delivery technology that enables development and manufacturing of gene therapies, supporting therapeutic DNA insertion for in vivo or ex vivo cell therapy contexts
- AAV platform: AAV-based vector development framework that produces and develops adeno-associated virus (AAV) vectors for gene therapy applications, enabling delivery of therapeutic DNA
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Oxford Biomedica
Futura Medical
HQ: United Kingdom
Website
- Description: Provider of proprietary transdermal solutions. Products include Eroxon, a topical gel for erectile dysfunction that helps men achieve an erection within 10 minutes without a prescription, and DermaSys, a patented platform for delivering treatments via the skin tailored to specific therapeutic indications and desired speed of onset and duration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Futura Medical company profile →
Oxford Pharmascience
HQ: United Kingdom
Website
- Description: Provider of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take, licensing its technologies and dossiers to a network of partners rather than manufacturing or selling directly to consumers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxford Pharmascience company profile →
Harvard Apparatus Regenerative Technology
HQ: United States
Website
- Description: Provider of regenerative implant technologies using Cellspan scaffolds seeded with patients’ stem cells, including esophageal and bronchial implants to repair tubular structures and reduce complications; applications for digestive tract disorders and patch technologies for reproductive tract disorders; and a consumer medicine division offering longevity products for Asia’s aging population.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Harvard Apparatus Regenerative Technology company profile →
Artizan Biosciences
HQ: United States
Website
- Description: Provider of drug discovery and development focused on diseases involving the human intestinal microbiota.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artizan Biosciences company profile →
LEAF Pharmaceuticals
HQ: United States
Website
- Description: Provider of biotechnology and healthcare products, including investigational anticancer drugs targeting solid tumors (LEAF-1401, LEAF-1701) with preclinical results showing reduced metastatic tumor burden in lung cancer models, superior performance in colorectal models, and minimal myelosuppression and gastrointestinal toxicity, plus LEAF-1404, a complex generic anticancer medicine manufactured under global cGMP.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LEAF Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Oxford Biomedica
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Oxford Biomedica
2.2 - Growth funds investing in similar companies to Oxford Biomedica
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Oxford Biomedica
4.2 - Public trading comparable groups for Oxford Biomedica
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →